Royalty Report: Drugs, Dermatology, Disease – Collection: 211946


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Dermatology
  • Disease
  • Skin care
  • Pharmaceuticals
  • Delivery
  • Therapeutic
  • Hair loss

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 211946

License Grant
Licensor grants a sole and exclusive license under the Licensed Patents and Licensors Proprietary Information relating to iodine to make, have made, use and sell Products, including prescription and OTC Products in the Territory, with no right to grant further sublicenses, except solely for the purposes of research and development and/or manufacture, but not distribution, of Products.
License Property
Licensor has certain proprietary technology relating to topical iodine.  The product means any pharmaceutical agent in the Field which includes iodine as an active ingredient.  The patents relate to iodine and its use.

Patented novel topical iodine products is for the treatment of acne as well as bacterial and fungal skin infection.

Field of Use
The field is the topical treatment of human skin diseases with iodine, expressly excluding the Excluded Applications of (a) wound care, (b) ocular infections, (c) vaginal infections, (d) oral applications, and (e) all topical antiseptic infection prevention applications.  It is the parties intent that the license set forth shall be specifically limited to prescription Products.

IPSCIO Record ID: 3507

License Grant
Under the agreement, Licensee received an exclusive worldwide perpetual irrevocable license to Licensor’s patented technology relating to an oral iodine pill.  Licensee entered into a collaboration and license with Licensor to license certain patents, patent applications, formulations and know-how relating to molecule iodine formulations used to manufacture an oral pill based on Licensor’s technology.
License Property
Our iodine dietary supplement product and the development of our molecular iodine prescription product build upon this licensed technology.

Patent US 5,589,198, Treatment of iodine deficiency diseases; US 5,885,592 Methods and pharmaceutical compositions for oral delivery of molecular iodine; US 6,248,335 Stabilized oral pharmaceutical composition containing iodide and iodate and method; US 6,432,426 Non-staining topical iodine composition and method; US 8,303,994 Method for the eradication of pathogens including S Aureus and antibiotic resistant microbes from the upper respiratory tract of mammals and for inhibiting the activation of immune cells.  US 2013-0039997 A1 Methods for inhibiting the activation of immune cells.

Field of Use
Licensee is currently preparing an IND application to enter Phase III clinical trials for the molecular iodine pill prescription product.   The rights granted apply to the healthcare industry relating to the drug pharmaceutical market.

IPSCIO Record ID: 230783

License Grant
Licensor hereby grants to Licensee an exclusive royalty-bearing license under the Licensor Technology to use, develop, market, advertise, promote, distribute, offer for sale, sell, export and import, but not Manufacture, the Product in the Territory for use in the Field, without the right to sublicense; provided Licensee shall have the right to grant a sublicense or otherwise enter into a marketing agreement with respect to the Product for Mexico and/or Canada.
License Property
Product means, individually or collectively, as the context requires, the formulation comprised of Dapsone in an SMP(TM) delivery system, including the Acne Product and any other current and future indication(s) (including indications for burn itch, acne rosacea, psoriasis and atopic dermatitis as determined by the JDMC) for all concentrations, sizes of volume, configurations and combinations of Dapsone in an SMP(TM) delivery system for use in the Field.

Dapsone means 4,4 diaminodiphenylsulfone and all salts, polymorphs and isomers thereof.

Licensor Patent Rights or Licensor Patent means
5,863,560 – Compositions and Methods for Topical Application of Therapeutic Agents
6,060,085 – Compositions and Methods for Topical Application of Therapeutic Agents
09/236,909 (*pending application)

SMP(TM) technology or SMP(TM) delivery system means a technology and delivery system consisting of a combination of a dissolved drug with a microparticle suspension of the drug to allow a controlled amount of the dissolved drug to permeate the epidermal layer of the skin. The SMP(TM) technology includes, but is not limited to, topical formulations containing Dapsone.

Acne Product means the 3% Acne Product or the 5% Acne Product and any other concentrations of the Product that may be used for the treatment of acne vulgaris, depending on the decision of the JDMC.

Field of Use
Field means the topical treatment of skin in humans.

IPSCIO Record ID: 279348

License Grant
Licensor grants
—  during the Research Term, a non-exclusive, worldwide, license, without the right to sublicense, under the Licensor Technology solely to perform Licensees obligations under the Research Plan; and
—  an exclusive, worldwide license, including the right to sublicense, under the Licensor Technology and Licensors interest in the Joint Patent Rights, to develop, make, have made, use, sell, have sold, offer for sale and import Selected Compounds and Products solely in the Licensee Field.
License Property
Licensor possesses scientific and proprietary technology and data and resources relating to the Hedgehog Pathway.  Hedgehog Pathway shall mean the biological signaling cascade which stimulates the transcription of various genes that mediate Hedgehog-dependent phenotypic cellular changes, as evidenced by the upregulation of transcription of Gli.

Product shall mean any final dosage form of a pharmaceutical product containing a Selected Compound for use in the Licensee Field.

Field of Use
Licensee possesses scientific and technical resources relating to the development and commercialization of pharmaceutical products for the treatment of skin diseases and/or disorders or for the promotion of hair growth in humans.

Licensor Field shall mean the local administration of Excluded Compounds for
—  the treatment or prevention of cardiovascular diseases and disorders in humans, including but not limited to the use of an Excluded Compound coated on a cardiovascular stent and ex vivo use of Excluded Compounds for the preparation of cells to be used in cell therapy applications; and/or any other indication in humans (excluding any indication within the Licensee Field) to which Licensor obtains rights from Third Party after the Effective Date; and/or
—  the Veterinary Field.  Veterinary Field shall mean Topical Application of a Licensed Compound for the treatment or prevention of any skin disease or disorder in animals, excluding humans.

Licensee Field shall mean the Topical Application of a Selected Compound or Product for the promotion of hair growth in humans (Hair Growth lndications); and/or any other indication in which Topical Application is used in humans – each, a Skin-Related Indication.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.